SCHEMBL6975645

SCHEMBL6975645

O=C(O)C1C=Nc2c(ccc3cc(C(=O)N4CCc5ccccc5C4)cnc23)C1=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.47
SMN1; SMN2 Q16637 5/20 0.46
HTT P42858 2/20 0.46
GAA P10253 1/20 0.43
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.40
SPR P35270 2/20 0.40
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
ADRA1A P35348 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6981271 0.88 HPGD (0.43) HPGDSMN1; SMN2HTTGAACHRNB4
SCHEMBL6985495 0.82 NPC1 (0.45) HPGDSMN1; SMN2HTTALDH1A1NPC1
SCHEMBL6981270 0.78 PSMD14 (0.43)
SCHEMBL6984771 0.77 PSMD14 (0.43) SMN1; SMN2
SCHEMBL6984460 0.74 HPGD (0.56) HPGDSMN1; SMN2HTTGAACHRNB4
SCHEMBL7799119 0.72 MEN1 (0.43) HPGDGAAALDH1A1
SCHEMBL7799355 0.71 HPGD (0.34) HPGDSMN1; SMN2ALDH1A1LMNA
SCHEMBL6985233 0.71 RELA (0.39) HPGDALDH1A1KDM4E
SCHEMBL7801069 0.70
SCHEMBL1509598 0.69 LMNA (0.43) HPGDSMN1; SMN2HTTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP claimed
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 HPGD 802/4885SMN1; SMN2 3757/4885HTT 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.